impact of expensing stock options better reflects the recurring
economic characteristics of its business.
(2) Other items -- Non-GAAP net loss and diluted net loss per common share
exclude other unusual or non-recurring items that are evaluated on an
individual basis. Amicus' evaluation of whether to exclude an item for
purposes of determining its non-GAAP financial measures considers both
the quantitative and qualitative aspects of the item, including, among
other things (i) its size and nature, (ii) whether or not it relates
to its ongoing business operations, and (iii) whether or not Amicus
expects it to occur as part of its normal business on a regular basis.
Items excluded for purposes of determining non-GAAP net loss and
diluted net loss per common share include deemed dividends, preferred
stock accretion, and changes in the fair value of warrant liability.
Conference Call and Webcast: First Quarter Financial Results
Amicus Therapeutics will host a conference call and webcast today, Tuesday, May 13, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-397-0284 (U.S./Canada) or 719-325-4871 (international).
The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.
A telephonic replay will also be available for seven days be
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved